Infectious Diseases Society of America guidelines on COVID-19 (search done on 4 April 2020)
Citation: Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clinical Infectious Diseases. 2020 Apr 27:ciaa478.
What is this? A variety of therapies have been suggested as treatments for patients with COVID-19.
In the systematic review prepared for a guideline from the Infectious Diseases Society of America, the authors searched for studies of the treatment of COVID-19 patients. They did not restrict their searches by type or language of publication and searched for articles published from 1 January 2019 to 4 April 2020. The guideline panel used 13 studies as the evidence base for their recommendations.
What was found: Based on the evidence in the review, the guideline panel recommended that for patients who had been admitted to hospital with COVID-19, hydroxychloroquine/chloroquine should be used in the context of a clinical trial.
Based on the evidence in the review, the guideline panel recommended that for patients who had been admitted to hospital with COVID-19, hydroxychloroquine/chloroquine plus azithromycin should only be used in the context of a clinical trial.
Based on the evidence in the review, the guideline panel recommended that for patients who had been admitted to hospital with COVID-19, lopinavir/ritonavir should only be used in the context of a clinical trial.
Based on the evidence in the review, the guideline panel suggest against the use of corticosteroid for patients who had been admitted to hospital with COVID-19 pneumonia.
Based on the evidence in the review, the guideline panel recommended that for patients who had been admitted to hospital with acute respiratory distress syndrome (ARDS) due to COVID-19, corticosteroids should be used in the context of a clinical trial.
Based on the evidence in the review, the guideline panel recommended that for patients who had been admitted to hospital with COVID-19, tocilizumab should only be used in the context of a clinical trial.
Based on the evidence in the review, the guideline panel recommended that for patients who had been admitted to hospital with COVID-19, COVID-19 convalescent plasma should be used in the context of a clinical trial.